AUSTIN, Texas—John Fesko, President and Chief Business Officer of Natera, Inc. (NASDAQ:NTRA), recently sold shares of the company's common stock valued at approximately $65,192, according to a filing with the Securities and Exchange Commission. The transactions took place on October 21 and 22, with shares sold at prices ranging from $120.07 to $120.7572.
On October 21, Fesko sold 342 shares at a weighted average price of $120.7572, and on October 22, he sold an additional 199 shares at $120.07 per share. Following these transactions, Fesko retains ownership of 114,065 shares in the company.
The sales were made to satisfy tax withholding obligations related to the vesting of restricted stock units, under a pre-arranged trading plan intended to comply with Rule 10b5-1(c) of the Securities Exchange Act.
In other recent news, Natera Inc . has been granted a permanent injunction against NeoGenomics (NASDAQ:NEO)' RaDaR assay by the District Court for the Middle District of North Carolina, as part of its ongoing effort to protect its intellectual property rights in the genetic testing market. This development follows a preliminary injunction dated December 2023. The court's decision prohibits the use of NeoGenomics' assay, which Natera claims infringes on its '454 patent. Analyst firms Piper Sandler, TD Cowen, and Canaccord Genuity have maintained their positive stances on Natera, reiterating their price targets and Buy ratings.
Natera has also reported a 12% sequential revenue increase from the first quarter and a 58% surge year-over-year, prompting the company to project a 40% revenue growth compared to 2023. This growth has been bolstered by significant strides in personalized genetic testing and diagnostics, as well as the endorsement of Natera's Renasight test by the National Kidney Foundation for chronic kidney disease testing.
In anticipation of the Galaxy study results, Piper Sandler has maintained an Overweight rating on Natera, highlighting the potential of the company's Signatera test to shift oncological discussions. Similarly, TD Cowen and Canaccord Genuity have kept their Buy ratings on Natera, expressing optimism for the company's future prospects based on their presentations at the European Society for Medical Oncology conference and the forthcoming data from the CIRCULATE-Japan and GALAXY trials.
InvestingPro Insights
As John Fesko's recent stock sale draws attention to Natera, Inc. (NASDAQ:NTRA), it's worth examining some key financial metrics and insights provided by InvestingPro to gain a broader perspective on the company's performance and market position.
Natera has demonstrated impressive growth, with InvestingPro data showing a robust revenue growth of 46.13% over the last twelve months as of Q2 2024, reaching $1.36 billion. This strong performance is further emphasized by a remarkable 58.13% quarterly revenue growth in Q2 2024. These figures align with an InvestingPro Tip highlighting Natera's "High return over the last year," which is substantiated by an extraordinary 190.88% one-year price total return.
Despite this growth trajectory, InvestingPro Tips indicate that analysts do not anticipate the company will be profitable this year, and it has not been profitable over the last twelve months. This is reflected in the negative operating income of -$313.73 million for the last twelve months as of Q2 2024. However, it's important to note that Natera "Operates with a moderate level of debt" and "Liquid assets exceed short term obligations," suggesting a relatively stable financial position despite current unprofitability.
The stock's performance has been notably volatile, with InvestingPro data showing a 29.67% price total return over the past six months. This volatility is captured in an InvestingPro Tip stating that "Stock price movements are quite volatile," which investors should consider when evaluating Natera's stock.
For those seeking a more comprehensive analysis, InvestingPro offers 8 additional tips on Natera, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.